BENGALURU, India, January 15, 2025, – A global leader in biopharmaceutical innovation, Takeda (TSE:4502/NYSE:TAK) today announced the official opening of its Innovation Capability Center (ICC) in Bengaluru, India. As part of Takeda’s global digital transformation, which includes insourcing capabilities, digital solutions will be developed at this center. After successful openings in Slovakia and Mexico, this is Takeda’s first ICC in Asia. The company’s commitment to improving healthcare through creative solutions is supported by the ICC. For years to come, Takeda’s employees, the patients we serve, and the environment will all be impacted by these innovative solutions that will help us improve our operations.
The launch of ICC India represents Takeda’s strategic commitment to apply data and new digital technologies, such as artificial intelligence, having the potential to accelerate research and development with the ultimate goal of transforming the lives of patients. Takeda is focused on creating better health for people and a brighter future for the world, with a steadfast commitment to its core values: Integrity, Fairness, Honesty and Perseverance. With a rich history that dates back to 1781 in Osaka, Japan, Takeda has grown into a global biopharmaceutical leader, operating in approximately 80 countries, including in India for more than 13 years. The company’s mission in India focuses on ensuring sustainable access to health care, bolstered by strategic partnerships. Takeda’s diverse therapeutic portfolio addresses gastrointestinal disorders, rare diseases, immunology, oncology and vaccines, underscoring its commitment to data-driven innovation and transforming treatments.
The establishment of this capability center underlines Takeda’s ambition to transform into one of the most trusted, values-based, R&D-driven biopharmaceutical companies, tapping into Karnataka’s vibrant ecosystem of innovation to serve patient needs.
“The launch of our Bengaluru ICC is a pivotal moment for Takeda’s digital transformation journey,” said Gabriele Ricci, Chief Data and Technology Officer at Takeda. “Tapping into local talent is vital in our quest to create better health for people and a brighter future for the communities we serve. Investing in India’s remarkable talent and technological expertise underscores Takeda’s commitment leveraging local expertise to deliver innovative, data-driven solutions and sustainable growth.”
The ICC in India will develop key technology capabilities to fuel innovation by embracing data and digital solutions using an agile, patient-centric and solution focused approach. The ICC will concentrate on pioneering advancements across domains including:
- Artificial Intelligence (AI) and GenAI to enhance efficiency and predictive analytics in healthcare
- Device Engineering and Application Virtualization to drive innovation in product development and patient-centric solutions
- Data Science and Visualization to enable data-driven decision-making for improved patient outcomes
“India was a natural choice for Takeda’s first ICC in Asia,” said Tilak Banerjee, Head of Takeda ICC India. “This strategic commitment will generate new jobs and further the company’s global mission of delivering life-transforming treatments to patients.”
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
